Advertisement

Index by author

January 01, 1996; Volume 276,Issue 1

A

  1. Anderson, D J

    1. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
      M Gopalakrishnan, L M Monteggia, D J Anderson, E J Molinari, M Piattoni-Kaplan, D Donnelly-Roberts, S P Arneric and J P Sullivan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 289-297;

  2. Appleton, M L

    1. Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: correlation of 3-methyleneindolenine formation and protein-binding.
      J Thornton-Manning, M L Appleton, F J Gonzalez and G S Yost
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 21-29;

  3. Arnaudeau, S

    1. Beta adrenergic receptor activation attenuates the generation of inositol phosphates in the pregnant rat myometrium. Correlation with inhibition of Ca++ influx, a cAMP-independent mechanism.
      L D Khac, S Arnaudeau, N Lepretre, J Mironneau and S Harbon
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 130-136;

  4. Arneric, S P

    1. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
      M Gopalakrishnan, L M Monteggia, D J Anderson, E J Molinari, M Piattoni-Kaplan, D Donnelly-Roberts, S P Arneric and J P Sullivan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 289-297;

  5. Asin, K E

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

B

  1. Bader, J P

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

  2. Bagdon, W

    1. Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone.
      C P Peter, J Guy, M Shea, W Bagdon, W F Kline and W C Hayes
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 271-276;

  3. Balena, R

    1. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae.
      R Balena, A Markatos, J G Seedor, M Gentile, C Stark, C P Peter and G A Rodan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 277-283;

  4. Bartoszyk, G D

    1. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
      G D Bartoszyk, J Harting and K O Minck
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 41-48;

  5. Berti, F

    1. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes.
      G Rossoni, A Sala, F Berti, T Testa, C Buccellati, C Molta, R Muller-Peddinghaus, J Maclouf and G C Folco
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 335-341;

  6. Bianchi, B

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  7. Birkett, D J

    1. Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene.
      W Tassaneeyakul, D J Birkett, J W Edwards, M E Veronese, W Tassaneeyakul, R H Tukey and J O Miners
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 101-108;

  8. Boado, R J

    1. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
      D Wu, R J Boado and W M Pardridge
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 206-211;

  9. Born, S L

    1. Suppression of rat hepatic microsomal cytochromes P450 by cyclophosphamide is correlated with plasma thyroid hormone levels and displays differential strain sensitivity.
      J C Kraner, E T Morgan, T S Poet, S L Born, V L Burnett and J R Halpert
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 258-264;

  10. Bouchard, P

    1. Autoradiographic evidence for the modulation of in vivo sigma receptor labeling by neuropeptide Y and calcitonin gene-related peptide in the mouse brain.
      P Bouchard, F Roman, J L Junien and R Quirion
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 223-230;

  11. Boyd, M R

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

  12. Britton, D R

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  13. Brodie, M S

    1. The effects of clomipramine on the excitatory action of ethanol on dopaminergic neurons of the ventral tegmental area in vitro.
      R D Trifunović and M S Brodie
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 34-40;

  14. Brouwer, W G

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

  15. Bryant, C M

    1. Novel anti-inflammatory compounds prevent CD11b/CD18, alpha M beta 2 (Mac-1)-dependent neutrophil adhesion without blocking activation-induced changes in Mac-1.
      G Endemann, Y Feng, C M Bryant, G S Hamilton, J Perumattam, R E Mewshaw and D Y Liu
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 5-12;

  16. Buccellati, C

    1. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes.
      G Rossoni, A Sala, F Berti, T Testa, C Buccellati, C Molta, R Muller-Peddinghaus, J Maclouf and G C Folco
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 335-341;

  17. Buckheit, R W

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

  18. Burnett, V L

    1. Suppression of rat hepatic microsomal cytochromes P450 by cyclophosphamide is correlated with plasma thyroid hormone levels and displays differential strain sensitivity.
      J C Kraner, E T Morgan, T S Poet, S L Born, V L Burnett and J R Halpert
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 258-264;

  19. Burnstock, G

    1. A novel P1 purinoceptor activates an outward K+ current in follicular oocytes of Xenopus laevis.
      B F King, J Pintor, S Wang, A U Ziganshin, L E Ziganshina and G Burnstock
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 93-100;

C

  1. Cantor, C R

    1. Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice.
      D J Hnatowich, G Mardirossian, M Fogarasi, T Sano, C L Smith, C R Cantor, M Rusckowski and P Winnard
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 326-334;

  2. Cao, L S

    1. Binding of bupivacaine to human serum proteins, isolated albumin and isolated alpha-1-acid glycoprotein. Differences between the two enantiomers are partly due to cooperativity.
      J X Mazoit, L S Cao and K Samii
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 109-115;

  3. Chen, J

    1. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia.
      S H Graham, J Chen, J Q Lan and R P Simon
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 1-4;

  4. Chen, L Y

    1. Variable effects of L-arginine analogs on L-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms.
      L Y Chen and J L Mehta
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 253-257;

  5. Chen, Z

    1. ATP depletion by iodoacetate and cyanide in renal distal tubular cells.
      L H Lash, J J Tokarz, Z Chen, B M Pedrosi and E B Woods
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 194-205;

  6. Chin, M H

    1. The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions.
      M H Chin, C L Cioffi, M Garay, R F Neale, S S Shetty, D DelGrande, B Mugrage, M A Sills and K E Lipson
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 74-83;

  7. Christie, M J

    1. Tetrahydro-9-aminoacridine has mixed actions on muscarinic currents and blocks opioid currents in rat locus ceruleus neurons.
      P B Osborne and M J Christie
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 137-142;

  8. Chuang, D M

    1. Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells.
      C J Hough, R P Irwin, X M Gao, M A Rogawski and D M Chuang
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 143-149;

  9. Cioffi, C L

    1. The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions.
      M H Chin, C L Cioffi, M Garay, R F Neale, S S Shetty, D DelGrande, B Mugrage, M A Sills and K E Lipson
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 74-83;

  10. Conte, B

    1. Electrocorticographic desynchronization after application of visceral and somatic noxious stimuli in urethane-anesthetized rats: effect of intrathecal administration of tachykinin (NK 1 or NK 2) receptor antagonists.
      B Conte, C Cutrufo and S Manzini
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 212-218;

  11. Currens, M J

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

  12. Cutrufo, C

    1. Electrocorticographic desynchronization after application of visceral and somatic noxious stimuli in urethane-anesthetized rats: effect of intrathecal administration of tachykinin (NK 1 or NK 2) receptor antagonists.
      B Conte, C Cutrufo and S Manzini
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 212-218;

D

  1. Davis, L S

    1. The Chinese herbal remedy, T2, inhibits mitogen-induced cytokine gene transcription by T cells, but not initial signal transduction.
      X Tao, L S Davis, K Hashimoto and P E Lipsky
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 316-325;

  2. DelGrande, D

    1. The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions.
      M H Chin, C L Cioffi, M Garay, R F Neale, S S Shetty, D DelGrande, B Mugrage, M A Sills and K E Lipson
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 74-83;

  3. Diagne, A

    1. Cationized hyperimmune immunoglobulins: pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus-infected human-peripheral blood lymphocytes-severe combined immune deficiency mice.
      W M Pardridge, Y S Kang, A Diagne and J A Zack
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 246-252;

  4. Didomenico, S

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  5. Donevan, S D

    1. Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite.
      S Subramaniam, S D Donevan and M A Rogawski
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 161-168;

  6. Donnelly-Roberts, D

    1. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
      M Gopalakrishnan, L M Monteggia, D J Anderson, E J Molinari, M Piattoni-Kaplan, D Donnelly-Roberts, S P Arneric and J P Sullivan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 289-297;

  7. Duman, R S

    1. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens.
      K L Widnell, D W Self, S B Lane, D S Russell, V A Vaidya, M J Miserendino, C S Rubin, R S Duman and E J Nestler
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 306-315;

  8. Dunn, C

    1. The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats.
      G Yue, F F Sun, C Dunn, K Yin and P Y Wong
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 265-270;

E

  1. Edwards, J W

    1. Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene.
      W Tassaneeyakul, D J Birkett, J W Edwards, M E Veronese, W Tassaneeyakul, R H Tukey and J O Miners
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 101-108;

  2. Edwards, R M

    1. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes.
      R M Edwards, W Trizna, E J Stack and J Weinstock
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 125-129;

  3. Endemann, G

    1. Novel anti-inflammatory compounds prevent CD11b/CD18, alpha M beta 2 (Mac-1)-dependent neutrophil adhesion without blocking activation-induced changes in Mac-1.
      G Endemann, Y Feng, C M Bryant, G S Hamilton, J Perumattam, R E Mewshaw and D Y Liu
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 5-12;

F

  1. Farley, J M

    1. Acetylcholine-induced chloride current oscillations in swine tracheal smooth muscle cells.
      X Liu and J M Farley
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 178-186;

  2. Felauer, E E

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

  3. Feng, Y

    1. Novel anti-inflammatory compounds prevent CD11b/CD18, alpha M beta 2 (Mac-1)-dependent neutrophil adhesion without blocking activation-induced changes in Mac-1.
      G Endemann, Y Feng, C M Bryant, G S Hamilton, J Perumattam, R E Mewshaw and D Y Liu
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 5-12;

  4. Fogarasi, M

    1. Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice.
      D J Hnatowich, G Mardirossian, M Fogarasi, T Sano, C L Smith, C R Cantor, M Rusckowski and P Winnard
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 326-334;

  5. Folco, G C

    1. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes.
      G Rossoni, A Sala, F Berti, T Testa, C Buccellati, C Molta, R Muller-Peddinghaus, J Maclouf and G C Folco
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 335-341;

  6. Freel, R W

    1. Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport.
      M Hatch, R W Freel, S Shahinfar and N D Vaziri
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 187-193;

  7. Furukawa, S

    1. A catechol derivative (4-methylcatechol) accelerates the recovery from experimental acrylamide-induced neuropathy.
      K Saita, T Ohi, Y Hanaoka, S Furukawa, Y Furukawa, K Hayashi and S Matsukura
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 231-237;

  8. Furukawa, Y

    1. A catechol derivative (4-methylcatechol) accelerates the recovery from experimental acrylamide-induced neuropathy.
      K Saita, T Ohi, Y Hanaoka, S Furukawa, Y Furukawa, K Hayashi and S Matsukura
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 231-237;

G

  1. Gao, X M

    1. Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells.
      C J Hough, R P Irwin, X M Gao, M A Rogawski and D M Chuang
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 143-149;

  2. Garay, M

    1. The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions.
      M H Chin, C L Cioffi, M Garay, R F Neale, S S Shetty, D DelGrande, B Mugrage, M A Sills and K E Lipson
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 74-83;

  3. Gentile, M

    1. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae.
      R Balena, A Markatos, J G Seedor, M Gentile, C Stark, C P Peter and G A Rodan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 277-283;

  4. Gonzalez, F J

    1. Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: correlation of 3-methyleneindolenine formation and protein-binding.
      J Thornton-Manning, M L Appleton, F J Gonzalez and G S Yost
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 21-29;

  5. Gopalakrishnan, M

    1. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
      M Gopalakrishnan, L M Monteggia, D J Anderson, E J Molinari, M Piattoni-Kaplan, D Donnelly-Roberts, S P Arneric and J P Sullivan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 289-297;

  6. Graham, S H

    1. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia.
      S H Graham, J Chen, J Q Lan and R P Simon
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 1-4;

  7. Gulakowski, R J

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

  8. Guy, J

    1. Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone.
      C P Peter, J Guy, M Shea, W Bagdon, W F Kline and W C Hayes
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 271-276;

H

  1. Halpert, J R

    1. Suppression of rat hepatic microsomal cytochromes P450 by cyclophosphamide is correlated with plasma thyroid hormone levels and displays differential strain sensitivity.
      J C Kraner, E T Morgan, T S Poet, S L Born, V L Burnett and J R Halpert
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 258-264;

  2. Hamada, Y

    1. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
      N Hotta, N Koh, F Sakakibara, J Nakamura, Y Hamada, T Wakao, T Hara, K Mori, K Naruse, E Nakashima and N Sakamoto
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 49-55;

  3. Hamilton, G S

    1. Novel anti-inflammatory compounds prevent CD11b/CD18, alpha M beta 2 (Mac-1)-dependent neutrophil adhesion without blocking activation-induced changes in Mac-1.
      G Endemann, Y Feng, C M Bryant, G S Hamilton, J Perumattam, R E Mewshaw and D Y Liu
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 5-12;

  4. Hanaoka, Y

    1. A catechol derivative (4-methylcatechol) accelerates the recovery from experimental acrylamide-induced neuropathy.
      K Saita, T Ohi, Y Hanaoka, S Furukawa, Y Furukawa, K Hayashi and S Matsukura
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 231-237;

  5. Hara, T

    1. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
      N Hotta, N Koh, F Sakakibara, J Nakamura, Y Hamada, T Wakao, T Hara, K Mori, K Naruse, E Nakashima and N Sakamoto
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 49-55;

  6. Harbon, S

    1. Beta adrenergic receptor activation attenuates the generation of inositol phosphates in the pregnant rat myometrium. Correlation with inhibition of Ca++ influx, a cAMP-independent mechanism.
      L D Khac, S Arnaudeau, N Lepretre, J Mironneau and S Harbon
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 130-136;

  7. Harting, J

    1. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
      G D Bartoszyk, J Harting and K O Minck
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 41-48;

  8. Hashimoto, K

    1. The Chinese herbal remedy, T2, inhibits mitogen-induced cytokine gene transcription by T cells, but not initial signal transduction.
      X Tao, L S Davis, K Hashimoto and P E Lipsky
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 316-325;

  9. Hatanaka, K

    1. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
      M Shimizu-Sasamata, S Kawasaki-Yatsugi, M Okada, S Sakamoto, S Yatsugi, J Togami, K Hatanaka, J Ohmori, K Koshiya, S Usuda and K Murase
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 84-92;

  10. Hatch, M

    1. Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport.
      M Hatch, R W Freel, S Shahinfar and N D Vaziri
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 187-193;

  11. Hawranko, A A

    1. Biochemical and pharmacological characterization of multiple beta-endorphinergic antinociceptive systems in the rat periaqueductal gray.
      P J Monroe, A A Hawranko, D L Smith and D J Smith
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 65-73;

  12. Hayashi, K

    1. A catechol derivative (4-methylcatechol) accelerates the recovery from experimental acrylamide-induced neuropathy.
      K Saita, T Ohi, Y Hanaoka, S Furukawa, Y Furukawa, K Hayashi and S Matsukura
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 231-237;

  13. Hayes, W C

    1. Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone.
      C P Peter, J Guy, M Shea, W Bagdon, W F Kline and W C Hayes
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 271-276;

  14. Hnatowich, D J

    1. Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice.
      D J Hnatowich, G Mardirossian, M Fogarasi, T Sano, C L Smith, C R Cantor, M Rusckowski and P Winnard
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 326-334;

  15. Hodges, L

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  16. Hollingsworth, Z R

    1. Inhibition of N-methyl-D-aspartate glutamate receptor subunit expression by antisense oligonucleotides reveals their role in striatal motor regulation.
      D G Standaert, C M Testa, G D Rudolf and Z R Hollingsworth
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 342-352;

  17. Hong, Y

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  18. Hotta, N

    1. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
      N Hotta, N Koh, F Sakakibara, J Nakamura, Y Hamada, T Wakao, T Hara, K Mori, K Naruse, E Nakashima and N Sakamoto
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 49-55;

  19. Hough, C J

    1. Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells.
      C J Hough, R P Irwin, X M Gao, M A Rogawski and D M Chuang
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 143-149;

  20. Hussain, T

    1. 125I-APE binding to adenosine receptors in coronary artery: photoaffinity labeling with 125I-azidoAPE.
      T Hussain, J Linden and S J Mustafa
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 284-288;

I

  1. Irwin, R P

    1. Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells.
      C J Hough, R P Irwin, X M Gao, M A Rogawski and D M Chuang
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 143-149;

J

  1. Jackson, E K

    1. Tachyphylaxis to angiotensin II and [Phe4]-angiotensin II in the rat mesentery in vivo.
      S P Tofovic and E K Jackson
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 13-20;

  2. Jenner, P

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  3. Johns, R A

    1. Determination of Km for oxygen of nitric oxide synthase isoforms.
      A Rengasamy and R A Johns
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 30-33;

  4. Jones, G S

    1. Evidence that a nereistoxin metabolite, and not nereistoxin itself, reduces neuronal nicotinic receptors: studies in the whole chick ciliary ganglion, on isolated neurons and immunoprecipitated receptors.
      Y Xie, T McHugh, J McKay, G S Jones and R H Loring
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 169-177;

  5. Junien, J L

    1. Autoradiographic evidence for the modulation of in vivo sigma receptor labeling by neuropeptide Y and calcitonin gene-related peptide in the mouse brain.
      P Bouchard, F Roman, J L Junien and R Quirion
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 223-230;

K

  1. Kang, Y S

    1. Cationized hyperimmune immunoglobulins: pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus-infected human-peripheral blood lymphocytes-severe combined immune deficiency mice.
      W M Pardridge, Y S Kang, A Diagne and J A Zack
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 246-252;

  2. Kawasaki-Yatsugi, S

    1. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
      M Shimizu-Sasamata, S Kawasaki-Yatsugi, M Okada, S Sakamoto, S Yatsugi, J Togami, K Hatanaka, J Ohmori, K Koshiya, S Usuda and K Murase
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 84-92;

  3. Khac, L D

    1. Beta adrenergic receptor activation attenuates the generation of inositol phosphates in the pregnant rat myometrium. Correlation with inhibition of Ca++ influx, a cAMP-independent mechanism.
      L D Khac, S Arnaudeau, N Lepretre, J Mironneau and S Harbon
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 130-136;

  4. King, B F

    1. A novel P1 purinoceptor activates an outward K+ current in follicular oocytes of Xenopus laevis.
      B F King, J Pintor, S Wang, A U Ziganshin, L E Ziganshina and G Burnstock
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 93-100;

  5. Kline, W F

    1. Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone.
      C P Peter, J Guy, M Shea, W Bagdon, W F Kline and W C Hayes
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 271-276;

  6. Koh, N

    1. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
      N Hotta, N Koh, F Sakakibara, J Nakamura, Y Hamada, T Wakao, T Hara, K Mori, K Naruse, E Nakashima and N Sakamoto
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 49-55;

  7. Koob, G F

    1. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats.
      F Rodríguez de Fonseca, P Rubio, F Menzaghi, E Merlo-Pich, J Rivier, G F Koob and M Navarro
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 56-64;

  8. Koshiya, K

    1. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
      M Shimizu-Sasamata, S Kawasaki-Yatsugi, M Okada, S Sakamoto, S Yatsugi, J Togami, K Hatanaka, J Ohmori, K Koshiya, S Usuda and K Murase
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 84-92;

  9. Kraner, J C

    1. Suppression of rat hepatic microsomal cytochromes P450 by cyclophosphamide is correlated with plasma thyroid hormone levels and displays differential strain sensitivity.
      J C Kraner, E T Morgan, T S Poet, S L Born, V L Burnett and J R Halpert
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 258-264;

L

  1. Lan, J Q

    1. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia.
      S H Graham, J Chen, J Q Lan and R P Simon
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 1-4;

  2. Lane, S B

    1. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens.
      K L Widnell, D W Self, S B Lane, D S Russell, V A Vaidya, M J Miserendino, C S Rubin, R S Duman and E J Nestler
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 306-315;

  3. Lash, L H

    1. ATP depletion by iodoacetate and cyanide in renal distal tubular cells.
      L H Lash, J J Tokarz, Z Chen, B M Pedrosi and E B Woods
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 194-205;

  4. Lepretre, N

    1. Beta adrenergic receptor activation attenuates the generation of inositol phosphates in the pregnant rat myometrium. Correlation with inhibition of Ca++ influx, a cAMP-independent mechanism.
      L D Khac, S Arnaudeau, N Lepretre, J Mironneau and S Harbon
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 130-136;

  5. Lin, C W

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  6. Lin, Q

    1. The role of 5-HT3 receptors in periaqueductal gray-induced inhibition of nociceptive dorsal horn neurons in rats.
      Y B Peng, Q Lin and W D Willis
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 116-124;

  7. Linden, J

    1. 125I-APE binding to adenosine receptors in coronary artery: photoaffinity labeling with 125I-azidoAPE.
      T Hussain, J Linden and S J Mustafa
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 284-288;

  8. Lipsky, P E

    1. The Chinese herbal remedy, T2, inhibits mitogen-induced cytokine gene transcription by T cells, but not initial signal transduction.
      X Tao, L S Davis, K Hashimoto and P E Lipsky
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 316-325;

  9. Lipson, K E

    1. The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions.
      M H Chin, C L Cioffi, M Garay, R F Neale, S S Shetty, D DelGrande, B Mugrage, M A Sills and K E Lipson
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 74-83;

  10. Liu, D Y

    1. Novel anti-inflammatory compounds prevent CD11b/CD18, alpha M beta 2 (Mac-1)-dependent neutrophil adhesion without blocking activation-induced changes in Mac-1.
      G Endemann, Y Feng, C M Bryant, G S Hamilton, J Perumattam, R E Mewshaw and D Y Liu
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 5-12;

  11. Liu, X

    1. Acetylcholine-induced chloride current oscillations in swine tracheal smooth muscle cells.
      X Liu and J M Farley
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 178-186;

  12. Loring, R H

    1. Evidence that a nereistoxin metabolite, and not nereistoxin itself, reduces neuronal nicotinic receptors: studies in the whole chick ciliary ganglion, on isolated neurons and immunoprecipitated receptors.
      Y Xie, T McHugh, J McKay, G S Jones and R H Loring
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 169-177;

M

  1. Maclouf, J

    1. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes.
      G Rossoni, A Sala, F Berti, T Testa, C Buccellati, C Molta, R Muller-Peddinghaus, J Maclouf and G C Folco
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 335-341;

  2. Mahan, L

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  3. Manzini, S

    1. Electrocorticographic desynchronization after application of visceral and somatic noxious stimuli in urethane-anesthetized rats: effect of intrathecal administration of tachykinin (NK 1 or NK 2) receptor antagonists.
      B Conte, C Cutrufo and S Manzini
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 212-218;

  4. Mardirossian, G

    1. Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice.
      D J Hnatowich, G Mardirossian, M Fogarasi, T Sano, C L Smith, C R Cantor, M Rusckowski and P Winnard
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 326-334;

  5. Markatos, A

    1. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae.
      R Balena, A Markatos, J G Seedor, M Gentile, C Stark, C P Peter and G A Rodan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 277-283;

  6. Matsukura, S

    1. A catechol derivative (4-methylcatechol) accelerates the recovery from experimental acrylamide-induced neuropathy.
      K Saita, T Ohi, Y Hanaoka, S Furukawa, Y Furukawa, K Hayashi and S Matsukura
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 231-237;

  7. Mazoit, J X

    1. Binding of bupivacaine to human serum proteins, isolated albumin and isolated alpha-1-acid glycoprotein. Differences between the two enantiomers are partly due to cooperativity.
      J X Mazoit, L S Cao and K Samii
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 109-115;

  8. McHugh, T

    1. Evidence that a nereistoxin metabolite, and not nereistoxin itself, reduces neuronal nicotinic receptors: studies in the whole chick ciliary ganglion, on isolated neurons and immunoprecipitated receptors.
      Y Xie, T McHugh, J McKay, G S Jones and R H Loring
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 169-177;

  9. McKay, J

    1. Evidence that a nereistoxin metabolite, and not nereistoxin itself, reduces neuronal nicotinic receptors: studies in the whole chick ciliary ganglion, on isolated neurons and immunoprecipitated receptors.
      Y Xie, T McHugh, J McKay, G S Jones and R H Loring
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 169-177;

  10. McMahon, J B

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

  11. Mehta, J L

    1. Variable effects of L-arginine analogs on L-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms.
      L Y Chen and J L Mehta
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 253-257;

  12. Menzaghi, F

    1. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats.
      F Rodríguez de Fonseca, P Rubio, F Menzaghi, E Merlo-Pich, J Rivier, G F Koob and M Navarro
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 56-64;

  13. Merlo-Pich, E

    1. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats.
      F Rodríguez de Fonseca, P Rubio, F Menzaghi, E Merlo-Pich, J Rivier, G F Koob and M Navarro
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 56-64;

  14. Mewshaw, R E

    1. Novel anti-inflammatory compounds prevent CD11b/CD18, alpha M beta 2 (Mac-1)-dependent neutrophil adhesion without blocking activation-induced changes in Mac-1.
      G Endemann, Y Feng, C M Bryant, G S Hamilton, J Perumattam, R E Mewshaw and D Y Liu
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 5-12;

  15. Michaelides, M

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  16. Mikusa, J

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  17. Miller, T

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  18. Minck, K O

    1. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
      G D Bartoszyk, J Harting and K O Minck
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 41-48;

  19. Miners, J O

    1. Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene.
      W Tassaneeyakul, D J Birkett, J W Edwards, M E Veronese, W Tassaneeyakul, R H Tukey and J O Miners
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 101-108;

  20. Mironneau, J

    1. Beta adrenergic receptor activation attenuates the generation of inositol phosphates in the pregnant rat myometrium. Correlation with inhibition of Ca++ influx, a cAMP-independent mechanism.
      L D Khac, S Arnaudeau, N Lepretre, J Mironneau and S Harbon
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 130-136;

  21. Miserendino, M J

    1. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens.
      K L Widnell, D W Self, S B Lane, D S Russell, V A Vaidya, M J Miserendino, C S Rubin, R S Duman and E J Nestler
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 306-315;

  22. Molinari, E J

    1. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
      M Gopalakrishnan, L M Monteggia, D J Anderson, E J Molinari, M Piattoni-Kaplan, D Donnelly-Roberts, S P Arneric and J P Sullivan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 289-297;

  23. Molta, C

    1. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes.
      G Rossoni, A Sala, F Berti, T Testa, C Buccellati, C Molta, R Muller-Peddinghaus, J Maclouf and G C Folco
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 335-341;

  24. Monroe, P J

    1. Biochemical and pharmacological characterization of multiple beta-endorphinergic antinociceptive systems in the rat periaqueductal gray.
      P J Monroe, A A Hawranko, D L Smith and D J Smith
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 65-73;

  25. Monteggia, L M

    1. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
      M Gopalakrishnan, L M Monteggia, D J Anderson, E J Molinari, M Piattoni-Kaplan, D Donnelly-Roberts, S P Arneric and J P Sullivan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 289-297;

  26. Morgan, E T

    1. Suppression of rat hepatic microsomal cytochromes P450 by cyclophosphamide is correlated with plasma thyroid hormone levels and displays differential strain sensitivity.
      J C Kraner, E T Morgan, T S Poet, S L Born, V L Burnett and J R Halpert
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 258-264;

  27. Mori, K

    1. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
      N Hotta, N Koh, F Sakakibara, J Nakamura, Y Hamada, T Wakao, T Hara, K Mori, K Naruse, E Nakashima and N Sakamoto
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 49-55;

  28. Mugrage, B

    1. The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions.
      M H Chin, C L Cioffi, M Garay, R F Neale, S S Shetty, D DelGrande, B Mugrage, M A Sills and K E Lipson
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 74-83;

  29. Muller-Peddinghaus, R

    1. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes.
      G Rossoni, A Sala, F Berti, T Testa, C Buccellati, C Molta, R Muller-Peddinghaus, J Maclouf and G C Folco
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 335-341;

  30. Murase, K

    1. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
      M Shimizu-Sasamata, S Kawasaki-Yatsugi, M Okada, S Sakamoto, S Yatsugi, J Togami, K Hatanaka, J Ohmori, K Koshiya, S Usuda and K Murase
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 84-92;

  31. Mustafa, S J

    1. 125I-APE binding to adenosine receptors in coronary artery: photoaffinity labeling with 125I-azidoAPE.
      T Hussain, J Linden and S J Mustafa
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 284-288;

N

  1. Nakamura, J

    1. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
      N Hotta, N Koh, F Sakakibara, J Nakamura, Y Hamada, T Wakao, T Hara, K Mori, K Naruse, E Nakashima and N Sakamoto
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 49-55;

  2. Nakashima, E

    1. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
      N Hotta, N Koh, F Sakakibara, J Nakamura, Y Hamada, T Wakao, T Hara, K Mori, K Naruse, E Nakashima and N Sakamoto
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 49-55;

  3. Narayanan, V L

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

  4. Naruse, K

    1. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
      N Hotta, N Koh, F Sakakibara, J Nakamura, Y Hamada, T Wakao, T Hara, K Mori, K Naruse, E Nakashima and N Sakamoto
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 49-55;

  5. Navarro, M

    1. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats.
      F Rodríguez de Fonseca, P Rubio, F Menzaghi, E Merlo-Pich, J Rivier, G F Koob and M Navarro
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 56-64;

  6. Neale, R F

    1. The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions.
      M H Chin, C L Cioffi, M Garay, R F Neale, S S Shetty, D DelGrande, B Mugrage, M A Sills and K E Lipson
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 74-83;

  7. Nestler, E J

    1. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens.
      K L Widnell, D W Self, S B Lane, D S Russell, V A Vaidya, M J Miserendino, C S Rubin, R S Duman and E J Nestler
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 306-315;

  8. Nikkel, A

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

O

  1. Ohi, T

    1. A catechol derivative (4-methylcatechol) accelerates the recovery from experimental acrylamide-induced neuropathy.
      K Saita, T Ohi, Y Hanaoka, S Furukawa, Y Furukawa, K Hayashi and S Matsukura
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 231-237;

  2. Ohmori, J

    1. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
      M Shimizu-Sasamata, S Kawasaki-Yatsugi, M Okada, S Sakamoto, S Yatsugi, J Togami, K Hatanaka, J Ohmori, K Koshiya, S Usuda and K Murase
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 84-92;

  3. Okada, M

    1. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
      M Shimizu-Sasamata, S Kawasaki-Yatsugi, M Okada, S Sakamoto, S Yatsugi, J Togami, K Hatanaka, J Ohmori, K Koshiya, S Usuda and K Murase
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 84-92;

  4. Omiecinski, C J

    1. Forskolin-mediated induction of CYP3A1 mRNA expression in primary rat hepatocytes is independent of elevated intracellular cyclic AMP.
      J S Sidhu and C J Omiecinski
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 238-245;

  5. Osborne, P B

    1. Tetrahydro-9-aminoacridine has mixed actions on muscarinic currents and blocks opioid currents in rat locus ceruleus neurons.
      P B Osborne and M J Christie
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 137-142;

P

  1. Pardridge, W M

    1. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
      D Wu, R J Boado and W M Pardridge
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 206-211;
    2. Cationized hyperimmune immunoglobulins: pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus-infected human-peripheral blood lymphocytes-severe combined immune deficiency mice.
      W M Pardridge, Y S Kang, A Diagne and J A Zack
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 246-252;

  2. Pedrosi, B M

    1. ATP depletion by iodoacetate and cyanide in renal distal tubular cells.
      L H Lash, J J Tokarz, Z Chen, B M Pedrosi and E B Woods
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 194-205;

  3. Peereboom-Stegeman, J H

    1. Uptake of cimetidine into syncytial microvillus membrane vesicles of human term placenta.
      E M van der Aa, A C Wouterse, C E Verrijt, J H Peereboom-Stegeman and F G Russel
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 219-222;

  4. Peng, Y B

    1. The role of 5-HT3 receptors in periaqueductal gray-induced inhibition of nociceptive dorsal horn neurons in rats.
      Y B Peng, Q Lin and W D Willis
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 116-124;

  5. Perumattam, J

    1. Novel anti-inflammatory compounds prevent CD11b/CD18, alpha M beta 2 (Mac-1)-dependent neutrophil adhesion without blocking activation-induced changes in Mac-1.
      G Endemann, Y Feng, C M Bryant, G S Hamilton, J Perumattam, R E Mewshaw and D Y Liu
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 5-12;

  6. Peter, C P

    1. Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone.
      C P Peter, J Guy, M Shea, W Bagdon, W F Kline and W C Hayes
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 271-276;
    2. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae.
      R Balena, A Markatos, J G Seedor, M Gentile, C Stark, C P Peter and G A Rodan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 277-283;

  7. Piattoni-Kaplan, M

    1. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
      M Gopalakrishnan, L M Monteggia, D J Anderson, E J Molinari, M Piattoni-Kaplan, D Donnelly-Roberts, S P Arneric and J P Sullivan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 289-297;

  8. Pintor, J

    1. A novel P1 purinoceptor activates an outward K+ current in follicular oocytes of Xenopus laevis.
      B F King, J Pintor, S Wang, A U Ziganshin, L E Ziganshina and G Burnstock
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 93-100;

  9. Poet, T S

    1. Suppression of rat hepatic microsomal cytochromes P450 by cyclophosphamide is correlated with plasma thyroid hormone levels and displays differential strain sensitivity.
      J C Kraner, E T Morgan, T S Poet, S L Born, V L Burnett and J R Halpert
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 258-264;

Q

  1. Quirion, R

    1. Autoradiographic evidence for the modulation of in vivo sigma receptor labeling by neuropeptide Y and calcitonin gene-related peptide in the mouse brain.
      P Bouchard, F Roman, J L Junien and R Quirion
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 223-230;

R

  1. Rengasamy, A

    1. Determination of Km for oxygen of nitric oxide synthase isoforms.
      A Rengasamy and R A Johns
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 30-33;

  2. Rivier, J

    1. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats.
      F Rodríguez de Fonseca, P Rubio, F Menzaghi, E Merlo-Pich, J Rivier, G F Koob and M Navarro
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 56-64;

  3. Rodan, G A

    1. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae.
      R Balena, A Markatos, J G Seedor, M Gentile, C Stark, C P Peter and G A Rodan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 277-283;

  4. Rodríguez de Fonseca, F

    1. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats.
      F Rodríguez de Fonseca, P Rubio, F Menzaghi, E Merlo-Pich, J Rivier, G F Koob and M Navarro
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 56-64;

  5. Rogawski, M A

    1. Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells.
      C J Hough, R P Irwin, X M Gao, M A Rogawski and D M Chuang
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 143-149;
    2. Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite.
      S Subramaniam, S D Donevan and M A Rogawski
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 161-168;

  6. Roman, F

    1. Autoradiographic evidence for the modulation of in vivo sigma receptor labeling by neuropeptide Y and calcitonin gene-related peptide in the mouse brain.
      P Bouchard, F Roman, J L Junien and R Quirion
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 223-230;

  7. Rossoni, G

    1. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes.
      G Rossoni, A Sala, F Berti, T Testa, C Buccellati, C Molta, R Muller-Peddinghaus, J Maclouf and G C Folco
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 335-341;

  8. Rubin, C S

    1. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens.
      K L Widnell, D W Self, S B Lane, D S Russell, V A Vaidya, M J Miserendino, C S Rubin, R S Duman and E J Nestler
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 306-315;

  9. Rubio, P

    1. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats.
      F Rodríguez de Fonseca, P Rubio, F Menzaghi, E Merlo-Pich, J Rivier, G F Koob and M Navarro
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 56-64;

  10. Rudolf, G D

    1. Inhibition of N-methyl-D-aspartate glutamate receptor subunit expression by antisense oligonucleotides reveals their role in striatal motor regulation.
      D G Standaert, C M Testa, G D Rudolf and Z R Hollingsworth
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 342-352;

  11. Rusckowski, M

    1. Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice.
      D J Hnatowich, G Mardirossian, M Fogarasi, T Sano, C L Smith, C R Cantor, M Rusckowski and P Winnard
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 326-334;

  12. Russel, F G

    1. Uptake of cimetidine into syncytial microvillus membrane vesicles of human term placenta.
      E M van der Aa, A C Wouterse, C E Verrijt, J H Peereboom-Stegeman and F G Russel
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 219-222;

  13. Russell, D S

    1. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens.
      K L Widnell, D W Self, S B Lane, D S Russell, V A Vaidya, M J Miserendino, C S Rubin, R S Duman and E J Nestler
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 306-315;

  14. Russell, J D

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

S

  1. Saita, K

    1. A catechol derivative (4-methylcatechol) accelerates the recovery from experimental acrylamide-induced neuropathy.
      K Saita, T Ohi, Y Hanaoka, S Furukawa, Y Furukawa, K Hayashi and S Matsukura
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 231-237;

  2. Sakakibara, F

    1. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
      N Hotta, N Koh, F Sakakibara, J Nakamura, Y Hamada, T Wakao, T Hara, K Mori, K Naruse, E Nakashima and N Sakamoto
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 49-55;

  3. Sakamoto, N

    1. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
      N Hotta, N Koh, F Sakakibara, J Nakamura, Y Hamada, T Wakao, T Hara, K Mori, K Naruse, E Nakashima and N Sakamoto
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 49-55;

  4. Sakamoto, S

    1. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
      M Shimizu-Sasamata, S Kawasaki-Yatsugi, M Okada, S Sakamoto, S Yatsugi, J Togami, K Hatanaka, J Ohmori, K Koshiya, S Usuda and K Murase
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 84-92;

  5. Sala, A

    1. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes.
      G Rossoni, A Sala, F Berti, T Testa, C Buccellati, C Molta, R Muller-Peddinghaus, J Maclouf and G C Folco
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 335-341;

  6. Samii, K

    1. Binding of bupivacaine to human serum proteins, isolated albumin and isolated alpha-1-acid glycoprotein. Differences between the two enantiomers are partly due to cooperativity.
      J X Mazoit, L S Cao and K Samii
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 109-115;

  7. Sano, T

    1. Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice.
      D J Hnatowich, G Mardirossian, M Fogarasi, T Sano, C L Smith, C R Cantor, M Rusckowski and P Winnard
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 326-334;

  8. Schultz, R J

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

  9. Seedor, J G

    1. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae.
      R Balena, A Markatos, J G Seedor, M Gentile, C Stark, C P Peter and G A Rodan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 277-283;

  10. Self, D W

    1. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens.
      K L Widnell, D W Self, S B Lane, D S Russell, V A Vaidya, M J Miserendino, C S Rubin, R S Duman and E J Nestler
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 306-315;

  11. Shahinfar, S

    1. Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport.
      M Hatch, R W Freel, S Shahinfar and N D Vaziri
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 187-193;

  12. Shea, M

    1. Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone.
      C P Peter, J Guy, M Shea, W Bagdon, W F Kline and W C Hayes
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 271-276;

  13. Shetty, S S

    1. The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions.
      M H Chin, C L Cioffi, M Garay, R F Neale, S S Shetty, D DelGrande, B Mugrage, M A Sills and K E Lipson
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 74-83;

  14. Shimizu-Sasamata, M

    1. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
      M Shimizu-Sasamata, S Kawasaki-Yatsugi, M Okada, S Sakamoto, S Yatsugi, J Togami, K Hatanaka, J Ohmori, K Koshiya, S Usuda and K Murase
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 84-92;

  15. Shiosaki, K

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  16. Shoemaker, R H

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

  17. Sidhu, J S

    1. Forskolin-mediated induction of CYP3A1 mRNA expression in primary rat hepatocytes is independent of elevated intracellular cyclic AMP.
      J S Sidhu and C J Omiecinski
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 238-245;

  18. Sills, M A

    1. The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions.
      M H Chin, C L Cioffi, M Garay, R F Neale, S S Shetty, D DelGrande, B Mugrage, M A Sills and K E Lipson
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 74-83;

  19. Simon, R P

    1. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia.
      S H Graham, J Chen, J Q Lan and R P Simon
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 1-4;

  20. Smith, C L

    1. Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice.
      D J Hnatowich, G Mardirossian, M Fogarasi, T Sano, C L Smith, C R Cantor, M Rusckowski and P Winnard
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 326-334;

  21. Smith, D J

    1. Biochemical and pharmacological characterization of multiple beta-endorphinergic antinociceptive systems in the rat periaqueductal gray.
      P J Monroe, A A Hawranko, D L Smith and D J Smith
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 65-73;

  22. Smith, D L

    1. Biochemical and pharmacological characterization of multiple beta-endorphinergic antinociceptive systems in the rat periaqueductal gray.
      P J Monroe, A A Hawranko, D L Smith and D J Smith
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 65-73;

  23. Smith, L

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  24. Stack, E J

    1. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes.
      R M Edwards, W Trizna, E J Stack and J Weinstock
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 125-129;

  25. Standaert, D G

    1. Inhibition of N-methyl-D-aspartate glutamate receptor subunit expression by antisense oligonucleotides reveals their role in striatal motor regulation.
      D G Standaert, C M Testa, G D Rudolf and Z R Hollingsworth
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 342-352;

  26. Stark, C

    1. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae.
      R Balena, A Markatos, J G Seedor, M Gentile, C Stark, C P Peter and G A Rodan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 277-283;

  27. Stashko, M

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  28. Stinson, S F

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

  29. Subramaniam, S

    1. Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite.
      S Subramaniam, S D Donevan and M A Rogawski
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 161-168;

  30. Sullivan, J P

    1. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
      M Gopalakrishnan, L M Monteggia, D J Anderson, E J Molinari, M Piattoni-Kaplan, D Donnelly-Roberts, S P Arneric and J P Sullivan
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 289-297;

  31. Sun, F F

    1. The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats.
      G Yue, F F Sun, C Dunn, K Yin and P Y Wong
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 265-270;

T

  1. Tao, X

    1. The Chinese herbal remedy, T2, inhibits mitogen-induced cytokine gene transcription by T cells, but not initial signal transduction.
      X Tao, L S Davis, K Hashimoto and P E Lipsky
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 316-325;

  2. Tassaneeyakul, W

    1. Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene.
      W Tassaneeyakul, D J Birkett, J W Edwards, M E Veronese, W Tassaneeyakul, R H Tukey and J O Miners
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 101-108;
    2. Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene.
      W Tassaneeyakul, D J Birkett, J W Edwards, M E Veronese, W Tassaneeyakul, R H Tukey and J O Miners
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 101-108;

  3. Testa, C M

    1. Inhibition of N-methyl-D-aspartate glutamate receptor subunit expression by antisense oligonucleotides reveals their role in striatal motor regulation.
      D G Standaert, C M Testa, G D Rudolf and Z R Hollingsworth
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 342-352;

  4. Testa, T

    1. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes.
      G Rossoni, A Sala, F Berti, T Testa, C Buccellati, C Molta, R Muller-Peddinghaus, J Maclouf and G C Folco
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 335-341;

  5. Thornton-Manning, J

    1. Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: correlation of 3-methyleneindolenine formation and protein-binding.
      J Thornton-Manning, M L Appleton, F J Gonzalez and G S Yost
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 21-29;

  6. Tofovic, S P

    1. Tachyphylaxis to angiotensin II and [Phe4]-angiotensin II in the rat mesentery in vivo.
      S P Tofovic and E K Jackson
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 13-20;

  7. Togami, J

    1. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
      M Shimizu-Sasamata, S Kawasaki-Yatsugi, M Okada, S Sakamoto, S Yatsugi, J Togami, K Hatanaka, J Ohmori, K Koshiya, S Usuda and K Murase
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 84-92;

  8. Tokarz, J J

    1. ATP depletion by iodoacetate and cyanide in renal distal tubular cells.
      L H Lash, J J Tokarz, Z Chen, B M Pedrosi and E B Woods
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 194-205;

  9. Trifunović, R D

    1. The effects of clomipramine on the excitatory action of ethanol on dopaminergic neurons of the ventral tegmental area in vitro.
      R D Trifunović and M S Brodie
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 34-40;

  10. Trizna, W

    1. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes.
      R M Edwards, W Trizna, E J Stack and J Weinstock
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 125-129;

  11. Tukey, R H

    1. Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene.
      W Tassaneeyakul, D J Birkett, J W Edwards, M E Veronese, W Tassaneeyakul, R H Tukey and J O Miners
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 101-108;

U

  1. Usuda, S

    1. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
      M Shimizu-Sasamata, S Kawasaki-Yatsugi, M Okada, S Sakamoto, S Yatsugi, J Togami, K Hatanaka, J Ohmori, K Koshiya, S Usuda and K Murase
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 84-92;

V

  1. Vaidya, V A

    1. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens.
      K L Widnell, D W Self, S B Lane, D S Russell, V A Vaidya, M J Miserendino, C S Rubin, R S Duman and E J Nestler
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 306-315;

  2. van der Aa, E M

    1. Uptake of cimetidine into syncytial microvillus membrane vesicles of human term placenta.
      E M van der Aa, A C Wouterse, C E Verrijt, J H Peereboom-Stegeman and F G Russel
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 219-222;

  3. Vaziri, N D

    1. Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport.
      M Hatch, R W Freel, S Shahinfar and N D Vaziri
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 187-193;

  4. Veronese, M E

    1. Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene.
      W Tassaneeyakul, D J Birkett, J W Edwards, M E Veronese, W Tassaneeyakul, R H Tukey and J O Miners
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 101-108;

  5. Verrijt, C E

    1. Uptake of cimetidine into syncytial microvillus membrane vesicles of human term placenta.
      E M van der Aa, A C Wouterse, C E Verrijt, J H Peereboom-Stegeman and F G Russel
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 219-222;

  6. Vistica, D T

    1. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
      J B McMahon, R W Buckheit, R J Gulakowski, M J Currens, D T Vistica, R H Shoemaker, S F Stinson, J D Russell, J P Bader, V L Narayanan, R J Schultz, W G Brouwer, E E Felauer and M R Boyd
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 298-305;

W

  1. Wakao, T

    1. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
      N Hotta, N Koh, F Sakakibara, J Nakamura, Y Hamada, T Wakao, T Hara, K Mori, K Naruse, E Nakashima and N Sakamoto
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 49-55;

  2. Wang, S

    1. A novel P1 purinoceptor activates an outward K+ current in follicular oocytes of Xenopus laevis.
      B F King, J Pintor, S Wang, A U Ziganshin, L E Ziganshina and G Burnstock
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 93-100;

  3. Weinstock, J

    1. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes.
      R M Edwards, W Trizna, E J Stack and J Weinstock
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 125-129;

  4. Widnell, K L

    1. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens.
      K L Widnell, D W Self, S B Lane, D S Russell, V A Vaidya, M J Miserendino, C S Rubin, R S Duman and E J Nestler
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 306-315;

  5. Williams, M

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  6. Willis, W D

    1. The role of 5-HT3 receptors in periaqueductal gray-induced inhibition of nociceptive dorsal horn neurons in rats.
      Y B Peng, Q Lin and W D Willis
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 116-124;

  7. Winnard, P

    1. Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice.
      D J Hnatowich, G Mardirossian, M Fogarasi, T Sano, C L Smith, C R Cantor, M Rusckowski and P Winnard
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 326-334;

  8. Witte, D

    1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
      K Shiosaki, P Jenner, K E Asin, D R Britton, C W Lin, M Michaelides, L Smith, B Bianchi, S Didomenico, L Hodges, Y Hong, L Mahan, J Mikusa, T Miller, A Nikkel, M Stashko, D Witte and M Williams
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 150-160;

  9. Wong, P Y

    1. The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats.
      G Yue, F F Sun, C Dunn, K Yin and P Y Wong
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 265-270;

  10. Woods, E B

    1. ATP depletion by iodoacetate and cyanide in renal distal tubular cells.
      L H Lash, J J Tokarz, Z Chen, B M Pedrosi and E B Woods
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 194-205;

  11. Wouterse, A C

    1. Uptake of cimetidine into syncytial microvillus membrane vesicles of human term placenta.
      E M van der Aa, A C Wouterse, C E Verrijt, J H Peereboom-Stegeman and F G Russel
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 219-222;

  12. Wu, D

    1. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
      D Wu, R J Boado and W M Pardridge
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 206-211;

X

  1. Xie, Y

    1. Evidence that a nereistoxin metabolite, and not nereistoxin itself, reduces neuronal nicotinic receptors: studies in the whole chick ciliary ganglion, on isolated neurons and immunoprecipitated receptors.
      Y Xie, T McHugh, J McKay, G S Jones and R H Loring
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 169-177;

Y

  1. Yatsugi, S

    1. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
      M Shimizu-Sasamata, S Kawasaki-Yatsugi, M Okada, S Sakamoto, S Yatsugi, J Togami, K Hatanaka, J Ohmori, K Koshiya, S Usuda and K Murase
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 84-92;

  2. Yin, K

    1. The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats.
      G Yue, F F Sun, C Dunn, K Yin and P Y Wong
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 265-270;

  3. Yost, G S

    1. Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: correlation of 3-methyleneindolenine formation and protein-binding.
      J Thornton-Manning, M L Appleton, F J Gonzalez and G S Yost
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 21-29;

  4. Yue, G

    1. The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats.
      G Yue, F F Sun, C Dunn, K Yin and P Y Wong
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 265-270;

Z

  1. Zack, J A

    1. Cationized hyperimmune immunoglobulins: pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus-infected human-peripheral blood lymphocytes-severe combined immune deficiency mice.
      W M Pardridge, Y S Kang, A Diagne and J A Zack
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 246-252;

  2. Ziganshin, A U

    1. A novel P1 purinoceptor activates an outward K+ current in follicular oocytes of Xenopus laevis.
      B F King, J Pintor, S Wang, A U Ziganshin, L E Ziganshina and G Burnstock
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 93-100;

  3. Ziganshina, L E

    1. A novel P1 purinoceptor activates an outward K+ current in follicular oocytes of Xenopus laevis.
      B F King, J Pintor, S Wang, A U Ziganshin, L E Ziganshina and G Burnstock
      Journal of Pharmacology and Experimental Therapeutics January 1996, 276 (1) 93-100;
Back to top

In this issue